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INTRODUCTION
There is growing evidence that adipocytes regulate whole-body energy homeostasis and insulin sensitivity. A "Western lifestyle" including a high-fat diet and lack of exercise causes excessive fat accumulation in adipocytes, which in turn leads to obesity, a major risk factor for type 2 diabetes, hypertension, dyslipidemia and atherosclerosis. Underlying insulin resistance plays a pivotal role in the pathogenesis of these disorders; however, the mechanisms that link obesity and impaired insulin signaling are not fully understood. Obesity is associated with a low-grade inflammation characterized by macrophage infiltration into adipose tissue 1, 2 . Monocyte chemoattractant protein-1 (MCP-1), which recruits monocytes, leukocytes and other inflammatory cells, plays a crucial role in this process 3 . Insulin resistance and hepatic steatosis induced by a high-fat diet are reduced in MCP-1 KO mice 4 . It has been proposed that the capacity of adipose tissue to expand, rather than the absolute amount of adipose tissue, is critical for metabolic homeostasis. When this capacity is exceeded, lipid accumulates in skeletal muscle and liver, which, in turn, attenuates insulin action 5 . Therefore, understanding the mechanism by which new adipocytes are generated is important. The finding that approximately 10% of fat cells
are renewed annually at all adult ages and levels of body mass index indicates that the ability to provide newborn adipocytes is limited 6 . It is 4 generally considered that the mature adipocyte is unable to proliferate 7 and that it is generated from a mesenchymal stem cell in the adipose tissue 8 . In the first phase, this multipotent stem cell turns into a preadipocyte, which cannot be distinguished morphologically from the precursor stem cells. In the second phase, terminal differentiation, the preadipocyte acquires the characteristics of the mature adipocyte, including lipid droplets, insulin Adipose tissue is classified into visceral and subcutaneous adipose tissue according to its anatomical location in the body. Multiple lines of evidence indicate that an increase in visceral adipose tissue is associated with insulin resistance, hyperlipidemia, type 2 diabetes and atherosclerosis 9, 10 , whereas the finding that transplantation of subcutaneous adipose tissue improves insulin sensitivity 11 indicates a beneficial role for subcutaneous adipose tissue. Treatment with thiazolidinedione, which specifically targets PPARγ, increases subcutaneous adipose tissue and decreases visceral adipose tissue 12 , a process associated with improved insulin sensitivity.
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Thiazolidinedione treatment also decreases the cell size of adipocytes, with a concomitant increase in the number of cells 13 . These findings show that thiazolidinedione accelerates adipocyte hyperplasia, especially in subcutaneous adipose tissue; however, as its target, PPARγ, first appears during terminal differentiation, it is difficult to understand how this agent could have an effect on preadipocyte or mesenchymal stem cells.
Accordingly, two possibilities arise: the first is that thiazolidinedione might stimulate mature adipocytes to secrete substances that promote the proliferation of precursor cells; the second is that thiazolidinedione might directly induce the proliferation of mature adipocytes.
In this study, we investigated the mechanism by which pioglitazone (Pio), a member of the thiazolidinedione class of drugs, increases the number of adipocytes. First, we ascertained that mature adipocytes incorporate 5-bromo-2′-deoxyuridine (BrdU), a thymidine analog, which indicates that the mature adipocytes undergo DNA synthesis. Second, we found that Pio accelerated mature adipocyte proliferation in vivo and in vitro. We then screened for genes encoding proteins that could mediate the proliferative signals of PPARγ, and noted that a previous microarray study showed that proliferin (PLF) is upregulated by Pio, rosiglitazone and troglitazone 14 . We confirmed that Pio elevated the mRNA and protein level of PLF in 3T3-L1 adipocytes, and that this was associated with increased cell proliferation. Since PLF acts via a paracrine mechanism 15 , we found that treatment with an anti-PLF antibody resulted in reduced adipocyte proliferation in vivo and in vitro. 6 Taken together, our results indicate that PLF regulates adipocyte proliferation.
RESULTS

Effect of Pio on cell proliferation in adipose tissue
To evaluate cell proliferation, we used immunohistochemistry to measure BrdU incorporation into adipose tissue and non-adipose tissue (i.e., intestine). Because cell proliferation in adipose tissue is much less active than that in intestine (Fig. 1a) , repeated intraperitoneal injections of BrdU were required. A single BrdU injection labels cells for 5-6 h
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, and so we expected that cells in S-phase would be detected for approximately 12-18 h by our method. Because the animals were sacrificed 24 h after the first injection, the possibility that labeled cells might transform from preadipocytes into mature adipocytes was excluded. In the epididymus, BrdU-labeled cells were detected in the perivascular area, which consists of the stromal vascular fraction (SVF; Fig. 1b) . Furthermore, BrdU-labeled cells with the characteristics of mature adipocytes were observed (Fig. 1c) .
Double-color immunostaining for BrdU and the mature adipocyte-specific protein adiponectin confirmed that adiponectin was present in the cytoplasm of the BrdU-labeled cells (Fig. 1d) (Fig. 2b) . These results suggest that, in mature subcutaneous adipocytes, activation of PPARγ by its agonist Pio leads to an increase in the rate of proliferation. The pattern of PCNA protein expression levels in isolated mature adipocytes from subcutaneous and visceral fat (Fig. 2c ) was similar to that of BrdU incorporation (Fig. 2a,b) .
Moreover, the protein expression of PCNA was increased by Pio treatment in subcutaneous adipocytes (Fig. 2c) Fig. 3b ). Adiponectin was detected in more than 90% of re-seeded adipocytes, whereas Pref-1
was not detected in these cells ( Supplementary Fig. 3 ). Hence, we can rule out the possibility that the increases in cell number were due to contamination by preadipocytes. Furthermore, lipid droplets, a characteristic of mature adipocytes, were detected in more than 90% of the cells examined (Fig. 4a) . Supporting the results in Fig. 3b , BrdU incorporation in the 3T3-L1 adipocytes was increased by treatment with Pio or PGJ2 (control vs Pio; P=0.0494, control vs PGJ2; P=0.017: Fig. 3c,d ). Together, these results suggest that activation of PPARγ in fully differentiated 3T3-L1 adipocytes leads to cell proliferation. To further confirm whether these mature adipocytes are capable of proliferating, we performed cell cycle analyses using flow cytometry. Cells in G0/G1, S and G2/M phase were observed amongst the fully differentiated 3T3-L1 adipocytes (Fig. 3g ). In addition, we examined cell proliferation in primary cultures of subcutaneous and mesenteric adipocytes. Since passage of primary cultured mature adipocytes is difficult, differentiation was induced at 70% confluence. The efficiency of differentiation in the primary cultured adipocytes was inferior to that of 3T3-L1 adipocytes; however, we were able to discriminate the differentiated cells by staining for adiponectin. We These results indicate that DNA polymerase influenced the morphology and gene expression of mature adipocytes and support our contention that these cells proliferate.
Role of PLF on adipocyte proliferation
Next, we explored the factors regulating mature adipocyte proliferation.
Since we observed that proliferation was accelerated by Pio, we screened for genes regulated by the thiazolidinedione class of drugs. In published microarray data from 3T3-L1 adipocytes 14 , we noted that the growth factor PLF was significantly upregulated by three thiazolidinediones (i.e., Pio, rosiglitazone and troglitazone). PLF, also termed mitogen-regulated protein (MRP), is a member of the prolactin/growth hormone family, and is involved in the angiogenesis of placenta 19, 20 . PLF, secreted as a paracrine agent, binds to the insulin-like growth factor II (IGF-II)/ cation-independent mannose 6-phosphate (M6P) receptor, the signal of which can be mediated with Gi protein 21, 22 . Here, we detected PLF mRNA at day 2 after the initiation of differentiation of 3T3-L1 adipocytes; the 11 mRNA level then remained stable at days 5 and 9 ( Supplementary Fig. 4 ).
Four PLF/MRP genes, Plf1, Plf2, Mrp3 and Mrp4, have been cloned and shown to share 91% amino acid sequence identity 15 . To determine which subclass is expressed in 3T3-L1 adipocytes, PCR of PLF cDNA was performed as previously described 15 . Direct sequence analysis revealed that the PCR product completely coincided with PLF1 ( Supplementary Fig. 5 ).
Incubation with Pio increased PLF mRNA as well as protein levels in cell lysates and culture media ( We then examined the expression of the PLF protein in rat adipocytes. PLF was expressed abundantly in white adipose tissue and brown adipose tissue, whereas low PLF levels were detected in pancreas, liver and skeletal muscle ( Supplementary Fig. 7 ). Interestingly, PLF protein expression in epididymal and mesenteric fat was significantly higher than that in subcutaneous fat, and treatment with Pio significantly increased PLF expression in subcutaneous fat only (control vs Pio; P=0.001: Fig. 6a,b) .
These results were similar to the results for BrdU incorporation shown in Fig. 2b ., supporting our speculation that PLF regulates mature adipocyte proliferation in vivo. To confirm this, we studied the effect of an anti-PLF antibody in vivo. Administration of the anti-PLF antibody to mice resulted in a decrease of BrdU incorporation in adiponectin-positive epididymal adipocytes (P=0.006: Fig. 6c ). BrdU incorporation and elimination of PLF throughout the body resulted in a decrease of mature adipocytes proliferation.
DISCUSSION
In conclusion, our results strongly suggested that mature adipocytes have the ability to proliferate in adipose tissue, as well as in cultured adipocytes. PLF may contribute to the proliferation of these mature adipocytes.
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METHODS
Effect of Pio on cell proliferation in adipose tissue
Male Wistar rats weighing 250 g were treated with food containing either 0%, 0.005% or 0.025% Pio for 14 d. Then 200 mg/kg BrdU was intraperitoneally administered 3 times over a period of 12 h (i.e., every 4 h).
The rats were then sacrificed 12 h later, and subcutaneous, epididymal, mesenteric and perirenal fats were harvested. Animal care and experimental procedures were performed under the approval of the Animal Care
Committees of Gifu University School of Medicine.
Immunohistochemical staining
BrdU antibody staining of paraffin sections of the fat tissues was carried out using a BrdU In-Situ Detection Kit (Becton Dickinson, Franklin Lakes, NJ, USA). As a positive control, tissue from the small intestinal tract of the same animal was also harvested and immediately stained, as described above. Other immunostaining was preformed using aint-adiponectin 
Dot blot analysis
To confirm the hypothesis that mature adipocytes incorporate BrdU in vivo, 
Real-time PCR analysis
To determine the mRNA expression levels of PPARγ, aP2, LPL, fatty acid synthase (FAS), adiponectin and glyceraldehyde 3-phosphate dehydrogenase (GAPDH), real-time PCR analysis was performed using a Thermal Cycler Dice (TAKARA, Ohtsu, Japan). Expression levels, calculated as copy numbers in each sample, were normalized to the expression level of GAPDH. The primer sequences are described in the Supplementary Methods.
Antibody administration in vivo
C57BL-CR mice were injected intraperitoneally with either 4 mg/kg goat anti-PLF antibody (Santa Cruz) or goat IgG, in parallel, and then 27 administered with BrdU 24 h later, as described above. BrdU-labeled adipocytes were detected with double-color immunostaining using an anti-BrdU antibody and anti-adiponectin antibody.
Statistics
Statistical comparisons were performed with Student's t-test (Figs. 5a and 6c) and two-factor ANOVA ( Fig. 5c and 5d ). Other data were analyzed with one-factor ANOVA (Dunnett test). All statistical tests were two-tailed. Data are given as mean ± s.e.m.. Values of P < 0.05 were considered statistically significant.
Dot blot analysis
Isolated 
BrdU incorporation into primary cultured adipocytes
Primary cultured subcutaneous and mesenteric adipocytes were harvested as described previously 1 . Cells were cultured in Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 100 U/mL penicillin, and 0.1 mg/mL streptomycin, and seeded in a 6-well plate or chamber slide. When the cells reached 70% confluence, the medium was changed to differentiation medium (DS Pharma Biomedical). Two days later, the medium was exchanged for DMEM, and differentiated adipocytes were 
Primer sequences
Quantitative real-time RT-PCR was performed for the validation of microarray results using the Thermal Cycler Dice Real Time System (TAKARA). Total RNA was isolated and purified as mentioned above.
Reverse transcription was performed using a PrimeScript Reverse cycles at 95℃for 5s, 60-62℃ for 30s. Oligonucleotide primers were
